The quality issues of biopharmaceutical therapeutics are definitely different from chemical drugs because of the increased complexity of manufacturing processes and complexity of the biologic molecules themselves. There is an increasing need for detailed product… Read more >
Ken Fountain, Director of Biopharmaceutical Business Development at Waters, recently returned from an insightful trip to Asia where he visited Waters customers in South Korea and attended the China Biopharma Executive Summit in Shanghai, in… Read more >
As regulators focus in on the critical quality attributes of biotherapeutics, what can biopharmaceutical labs in late development or QC do to increase confidence in their bioseparations – other than to run more assays?
ProteinWorks and GlycoWorks kits address more than sample prep challenges One of the most challenging parts of an LC-MS workflow happens before analytical chemists even turn to their instrument: Sample preparation. Get it right, and… Read more >
How quickly can you go from glycosylated protein to glycan fragment confirmation? Now, analyzing released N-glycans takes about as much time as it does for Tom Brady and the New England Patriots to erase… Read more >
Close to sixty scientists from across Western Europe gathered for the Peptide Bioanalysis Forum held on-site at Ferring Pharmaceuticals A/S in Copenhagen on February 3-4, 2015. A collaborative effort between Ferring Pharmaceuticals and Waters Corporation,… Read more >
Peptides and proteins are not small molecules. Why treat them the same? Analyzing large molecules may be one of the greatest challenges that the bioanalyst faces at the beginning of the 21st century. Employing LC-MS for the… Read more >
One of the opportunities for personalized medicine is that by targeting a disease, can you eliminate the side effects of the cure? Antibody drug conjugates (ADCs) are one next-generation therapeutic approach that may have an… Read more >